Intravenous Prostacyclin in Acute Nonhemorrhagic Stroke

Completed

Phase 2 Results

Trial Description

To assess the therapeutic efficacy of prostacyclin in nonhemorrhagic cerebral infarction.

Interventions

  • Prostacyclin (Epoprostenol)Drug
    Intervention Desc: Prostaglandin, presumed vasodilator.

Trial Design

Randomized, placebo-controlled, double-blind trial involving 80 patients at 5 centers.

Patient Involvement

Patients in the prostacyclin group received a continuous IV infusion of prostacyclin or placebo at an average rate of 8.5 ng/kg/min for 72 hours.

Outcomes

Type Measure Time Frame Safety Issue
Primary Hemodynamic changes, neurologic deficit scores as determined on admission, at Day 3, and at Weeks 1, 2, and 4.